SINTX Revenue Jumps as Losses Narrow
SINTX Technologies reported third quarter 2026 revenue of about $2.2 million, up sharply from the prior-year period.
Updated on Nov. 5, 2026 in Corporate Finance
SINTX Technologies reported total revenue of approximately $2.2 million for the third quarter of 2026, compared with $208,000 a year earlier. The company also said its net loss narrowed to about $1.6 million from $3.5 million.
Why it matters
The results show a sharp shift in the company's revenue base and cost structure after the limited-use release of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System. The results also come as the company regained compliance with Nasdaq's minimum stockholders' equity requirement.
Gross margin rose to roughly 62% from 45% a year earlier, while total operating expenses fell 13% to $3.0 million. Nine-month revenue reached about $3.0 million, up 315%, though the filing does not detail sustainability of these trends.
The players
SINTX Technologies
SINTX Technologies is a Salt Lake City-based materials science company that develops silicon nitride ceramics for medical applications.
Nasdaq
Nasdaq is a major U.S. stock exchange that sets listing standards, including minimum stockholders' equity requirements for listed companies.
The details
SINTX ended the quarter with approximately $2.0 million in cash after receiving about $2.0 million in gross proceeds from the exercise of 941,423 Class B warrants at $2.14 per share. The warrant exercise followed a post-quarter call triggered by the company reaching its third-quarter revenue milestone of $2 million.
Timeline
January 2026: Limited-use release of the SiNAPTIC system began.
September 30, 2026: Third quarter ended.
November 5, 2026: Third quarter results were announced.
First quarter 2027: Large-animal studies of silicon nitride-treated medical textiles are expected to be completed.
Market Dynamics
Regaining compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement places SINTX back within the listing standard that governs its continued exchange listing. The quarter's margin expansion and revenue growth come as the company works to build a sustained revenue base from its medical device line.
The warrant exercise added roughly $2.0 million in cash and reduced the company's near-term funding pressure. Investors tracking the stock should weigh the narrower loss against a revenue base that is still small in absolute dollars.
The takeaway
Revenue growth and margin expansion are the key signals to watch in SINTX's coming quarters. Sustained gains would indicate the SiNAPTIC system is building a durable commercial base rather than a one-time lift.
What happens next
The company expects to complete large-animal in vivo studies of silicon nitride-treated medical textiles in the first quarter of 2027.
Further reading
Track more company earnings and capital moves in Corporate Finance coverage from Salt Lake City.
Source note: This article includes information reported by The Manila times.
